|
|
|
| Effect of Budesonide Suspension combined with Ipratropium Bromide in COPD patients and its influence on lung function |
| ZHANG Lei1 LI Weili2 WANG Chun3▲ |
1.Department of Pharmacy, the Fourth Affiliated Hospital of Anhui Medical University, Anhui Province, Hefei 230012, China;
2.the Hospital Office, Anhui Academy of Science and Technology, Anhui Province, Hefei 230088, China;
3.Institute of Clinical Pharmacology, Anhui Medical University, Anhui Province, Hefei 230032, China |
|
|
|
Abstract Objective To investigate the effect of Budesonide Suspension combined with Ipratropium Bromide in patients with chronic obstructive pulmonary disease (COPD) and its effect on lung function. Methods A total of 100 COPD patients admitted to the Fourth Affiliated Hospital of Anhui Medical University from January to December 2019 were selected and divided into observation group and control group according to random number table method, with 50 patients in each group. The control group was treated with Budesonide Suspension, and the observation group was treated with Budesonide Suspension combined with Ipratropium Bromide for 10 days. The lung function (forced expiratory volume in the first second [FEV1], forced vital capacity [FVC], FEV1/FVC), inflammatory factors (tumor necrosis factor-α [TNF-α], hypersensitivity C-reactive protein [hs-CRP]) were compared between the two groups before treatment and 10 days after treatment, and the changes of signs, remission time of clinical symptoms, length of hospital stay and the incidence of adverse reactions were recorded. Results The length of hospital stay, disappearance time of shortness of breath and dyspnea, disappearance time of lung signs, disappearance time of asthma and relief time of cough in the observation group were significantly shorter than those in the control group, with statistical significance (all P ＜ 0.05). After treatment, the levels of FEV1, FVC and FEV1/FVC of lung function in the observation group were higher than those in the control group, while the levels of TNF-α and hs-CRP in the observation group were lower than those in the control group, with statistical significance (all P ＜ 0.05). Conclusion The combination of drugs has significant therapeutic effect and high safety for COPD patients.
|
|
|
|
|
|
[1] 蒋艳秋，夏阳，袁毅.雾化吸入较大剂量布地奈德治疗COPD急性加重期的临床探究[J].中国急救医学，2018， 38（z1）：41.
[2] 邓明玲，巴燕，温奕超.稳定期辨证用药对慢性阻塞性肺疾病频繁急性加重表型的获益评价[J].中国实验方剂学杂志，2018，24（16）：182-187.
[3] 罗瑜，张剑青，赵芝焕. 长链非编码RNA在慢性阻塞性肺疾病发病机制中的研究进展[J].实用医学杂志，2018， 34（21）：12-14.
[4] Fanny W Ko，Ka Pang Chan，David S Hui，et al. Acute exacerbation of COPD [J]. Respirology，2016，21（7）：1152-1165.
[5] 王伟伟，贾军辉，刘媛，等.脾多肽联合布地奈德雾化吸入对COPD急性加重期患者肺功能及动脉血气指标的影响[J].中国地方病防治杂志，2017，32（8）：919.
[6] MacGregor TR，ZuWallack R，Rubano V，et al. Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler [J]. Clin Transl Sci，2016，9（2）：105-113.
[7] Kola M，Hac?覦o■lu D，Erd?觟l H，et al. Bilateral Acute Angle Closure Developing Due to Use of Ipratropium Bromide and Salbutamol [J]. Int Ophthalmol，2018，38（1）：385-388.
[8] 嵇华夏，周勤，孙书明.哮喘-慢性阻塞性肺疾病重叠的临床研究和诊断标准进展[J].中国呼吸与危重监护杂志，2017，16（4）：407-413.
[9] 雷新锋，李凝香，于立杰.痰热清联合头孢哌酮舒巴坦对COPD患者临床疗效及炎症细胞因子水平的影响[J].中国中西医结合急救杂志，2018，25（6）：578-580.
[10] 刘晓姝，郭璐.布地奈德联合辛伐他汀对慢性阻塞性肺疾病大鼠炎症因子与肺组织病理的影响[J].中国现代医学杂志，2017，27（21）：7-11.
[11] 姜锋，陈刚，张爱清，等.噻托溴铵联合茶碱缓释片对稳定期COPD患者肺功能及呼吸困难指标的影响[J].山东医药，2017，57（6）：57-59.
[12] 王靓雅，刘冰，祖权，等.补肺健脾益肾方治疗稳定期慢性阻塞性肺疾病营养状况和对免疫功能的影响[J].中国实验方剂学杂志，2017，23（22）：182-187.
[13] Poh TY，Mac Aogáin M，Chan AK，et al. Understanding COPD-overlap syndromes [J]. Expert Rev Respir Med，2017，11（4）：285-298.
[14] 熊英，张金娟，黄惠妍，等.异丙托溴铵雾化吸入治疗对 COPD 大鼠肺功能的保护作用及机制[J].山东医药，2016， 56（21）：27-29.
[15] 李岩，陈志远，吴健华，等.盐酸戊乙奎醚联合术侧肺高频喷射通气对COPD患者单肺通气时肺功能及炎性反应的影响[J].中华麻醉学杂志，2018，38（10）：1169-1173.
[16] 胡建平，韩俊垒，边红芝.SAL/FP吸入联合噻托溴铵对COPD患者临床症状改善和肺功能的影响[J].重庆医学，2018，47（14）：97-98，101.
[17] Maselli DJ，Peters JI. ACP Journal Club. Review： In COPD，Tiotropium Improves Lung Function and Reduces Adverse Events Compared With Ipratropium Bromide [J]. Ann Intern Med，2016，164（2）：JC6.
[18] 吴清松，饶平.不同剂量布地奈德联合异丙托溴铵对AECOPD患者主观症状、肺功能及动脉血气指标的影响[J].中国药房，2016，27（20）：2816-2818，2819.
[19] 熊英，张金娟，黄惠妍，等.异丙托溴铵雾化吸入治疗对COPD大鼠肺功能的保护作用及机制[J].山东医药，2016，56（21）：27-29.
[20] 杨怀宇，石江涛.布地奈德联合复方异丙托溴铵雾化吸入对尘肺病大容量全肺灌洗围术期患者的疗效影响[J].中国药房，2017，28（5）：656-659.
[21] 李秋珍.异丙托溴铵联合沙丁胺醇雾化吸人治疗慢性阻塞性肺病的疗效[J].中国急救医学，2018，38（z2）：144.
[22] Liu X，Tang C，Xu H. Clinical effect of treatment on elderly chronic obstructive pulmonary disease combined with pulmonary tuberculosis [J]. Pak J Pharm Sci，2016， 29（6 Spec）：2255-2258.
[23] 朱彦秋，代福恒，侯海龙，等.甲泼尼龙联合布地奈德雾化吸入对AECOPD患者炎性因子及免疫功能的影响[J].疑难病杂志，2020，19（2）：122-126.
[24] 妥亚军，侯滨，张方，等.miR-21在COPD患者肺动脉高压形成及病情判断中的作用[J].山东医药，2018，58（36）：66-68.
[25] 陈建波，曹磊，蔡丽婷，等.布地奈德联合异丙托溴铵雾化吸入对慢性阻塞性肺疾病患者肺功能、炎症和血气指标的影响[J].中国医药科学，2020，10（8）：70-73.
[26] 张钰，毛旻，刘璐，等.不同浓度布地奈德联合复方异丙托溴铵对老年急性加重期慢性阻塞性肺疾病患者动脉血气及肺功能的影响[J].中国老年学杂志，2017，37（21）：5355-5357. |
|
|
|
